National drug regulators use evidence from clinical trials to decide whether new cancer drugs will be approved for use. But these studies are often flawed.
Academic rigor, journalistic flair
Articles on Cost of cancer drugs
Displaying all articles
Some argue the current system of subsidising drugs in Australia needs changing to accommodate new cancer therapies. But two recent drug listings show the current system is working perfectly well.
The high cost of cancer drugs in South Africa has come under the spotlight with an investigation by the Competition Commission in the country.
Top contributors
-
Senior lecturer, University of South Australia
-
Professor of Health Economics, Deputy Director of CHERE, University of Technology Sydney
-
Professor of Health Economics, University of Technology Sydney
-
Senior Research Fellow, University of Technology Sydney
-
Associate professor, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Associate Professor and Course Leader: Post Graduate Programmes in Clinical Pharmacy in the Department of Pharmacy, Sefako Makgatho Health Sciences University
